Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Coya Therapeutics, Inc.
< Previous
1
2
Next >
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
March 12, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
March 06, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
February 29, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
February 22, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
February 21, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
February 13, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
January 29, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
January 18, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
January 16, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
January 05, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
December 20, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
December 13, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
December 12, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces $26.5 Million Private Placement
December 06, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
December 06, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
RDY
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
November 08, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Announces Acceptance of Oral Presentation, “Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimer’s Disease: A Phase 1 Feasibility Study,” at the 18th International Conference on Alzheimer’s and Parkinson’s Disease in Lisbon
October 27, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)
October 09, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
October 05, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
October 03, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics to Present at the LD Micro Investor Conference
September 27, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)
September 22, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases
September 07, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies
August 31, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023
August 25, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya’s Board of Directors
August 21, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
August 08, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
August 03, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
July 19, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer’s Disease
July 17, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Tickers
COYA
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.